Analyst confidence swells following positive FDA alignment on the company's pivotal gene therapy trial for Rett Syndrome.
Permanent J-Code from CMS aims to streamline reimbursement and broaden patient access for its graft-versus-host disease treatment.
Genentech's Tecentriq combination therapy is the first maintenance treatment for extensive-stage small cell lung cancer, a significant advance in a hard-to-treat disease.
Regulators express significant doubts over the company's lead drug candidate, avacopan, sparking a massive investor sell-off.
The new oral treatment addresses chronic spontaneous urticaria in patients unresponsive to antihistamines, driving shares up over 2.7%.
Despite a revenue decline, the packaged foods giant reaffirmed its full-year guidance, signaling stability and boosting investor confidence.
Company receives a Complete Response Letter for its Menkes disease treatment, CUTX-101, citing manufacturing issues, not safety or efficacy concerns.
Despite posting the strongest first quarter in its history, the nation's largest egg producer fell short of Wall Street's revenue and profit expectations.